Compass Therapeutics, Inc. CMPX 深 沪
已收盘 03-27 16:00:00 美东时间
5.21
-0.120
-2.25%
华盛通- 最 高5.37
- 今 开5.29
- 成交量 135.59万股
- 最 低 5.15
- 昨 收 5.33
- 总市值 9.38亿
- 52周最高 6.88
- 市盈率 静 --
- 换手率 0.75%
- 52周最低 1.40
- 委 比 -82.02%
- 总股本 1.80亿
- 历史最高 6.88
- 量 比 0.58
- 振 幅 4.13%
- 历史最低 0.765
- 每 手 1
- 风险率 1.48%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅499.25%！Cabaletta Bio获Guggenheim升目标价至16美元，维持"买入"评级
今日重点评级关注：Guggenheim：维持Cabaletta Bio"买入"评级，目标价从15美元升至16美元；HC Wainwright & Co.：维持Palvella Therapeutics"买入"评级，目标价从255美元升至270美元
03-25 10:31
Guggenheim Reiterates Buy on Compass Therapeutics, Maintains $12 Price Target
Guggenheim analyst Michael Schmidt reiterates Compass Therapeutics (NASDAQ:CMPX) with a Buy and maintains $12 price target.
03-24 21:22
Compass Therapeutics GAAP EPS of -$0.09
Compass Therapeutics press release (CMPX): Q4 GAAP EPS of -$0.09. Net loss for the year ended December 31, 2025, was $66.5 million or $0.42 per common share, compared to $49.4 million or $0.36 per com...
03-06 06:07
Compass Therapeutics' 2025 net loss widens as R&D costs jump
Compass Therapeutics' 2025 net loss widens as R&D costs jump Overview Oncology-focused biopharma's net loss widened to $66.5 mln in 2025 Company's R&D expenses rose 32% due to increased manufacturing costs Cash and marketable securities at year-end 2025 were $209 mln, funding operations into 2028 Ou
03-05 20:37
Compass Therapeutics Q4 EPS $(0.09) Beats $(0.10) Estimate
Compass Therapeutics (NASDAQ:CMPX) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.10) by 12.62 percent. This is a 18.18 percent increase over losses of $(0.11) per share
03-05 20:36
Compass Therapeutics posts FY 2025 R&D expenses of USD 56.0 million, up 32%
Compass Therapeutics posts FY 2025 R&D expenses of USD 56.0 million, up 32% Compass Therapeutics reported a FY 2025 net loss of USD 66.5 million and a net loss per share of USD 0.42. R&D expenses rose 32% to USD 56.0 million, while G&A expenses increased 12% to USD 16.9 million. The company ended FY
03-05 20:30
Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update
Compass Therapeutics reported strong financial results for 2025 with $209 million in cash and marketable securities, providing runway into 2028. Key clinical updates include the COMPANION-002 Phase 2/3 study for tovecimig in biliary tract cancer reaching the prespecified OS event threshold, with PFS and OS data expected in April. Expansion cohorts for CTX-8371 in TNBC, NSCLC, and Hodgkin lymphoma are open, and the Phase 1 study for CTX-10726 will...
03-05 12:30
Monte Rosa Therapeutics, Ventyx Biosciences, United Microelectronics And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mixed, with the Dow Jones index falling around 0.2% on Wednesd...
01-07 23:03
美股大行评级 | 拼多多、小鹏获Freedom上调目标价；多家大行首予Wealthfront"超配"评级，目标价最高23美元
今日重点评级关注：HC Wainwright & Co.：维持MetaVia Inc."买入"评级，目标价从12美元升至40美元；Canaccord Genuity：维持GH Research"买入"评级，目标价从35美元升至39美元
01-07 17:25
D. Boral Capital Maintains Buy on Compass Therapeutics, Maintains $30 Price Target
D. Boral Capital analyst Jason Kolbert maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and maintains $30 price target.
01-06 22:39
